These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22574644)

  • 1. Improving long-term ACS management: is there a role for the new antiplatelets?
    Cohen M
    J Interv Cardiol; 2012 Oct; 25(5):425-32. PubMed ID: 22574644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions.
    Becker RC; Gibson CM; Jennings LK; Morrow DA
    Am J Cardiol; 2010 Oct; 106(8):S2-3. PubMed ID: 20920638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    Tcheng JE; Mackay SM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management.
    Cowley MJ; Kuritzky L
    Curr Med Res Opin; 2009 Jun; 25(6):1477-90. PubMed ID: 19419337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High platelet reactivity--the challenge of prolonged anticoagulation therapy after ACS.
    Brouwer MA; Jaspers Focks J; Verheugt FW
    Thromb Haemost; 2013 May; 109(5):799-807. PubMed ID: 23426079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antiplatelet agents in ACS: from pharmacology to clinical differences.
    Agewall S; Badimon L; Drouet L; Eschenhagen T; Husted S; Simon T; Steg G
    Fundam Clin Pharmacol; 2011 Oct; 25(5):564-71. PubMed ID: 21077944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care.
    Hankey GJ
    Cerebrovasc Dis; 2004; 17 Suppl 3():11-6. PubMed ID: 14730253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
    Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
    Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
    Huber K; Bates ER; Valgimigli M; Wallentin L; Kristensen SD; Anderson JL; Lopez Sendon JL; Tubaro M; Granger CB; Bode C; Ohman EM; Steg PG
    Am Heart J; 2014 Nov; 168(5):611-21. PubMed ID: 25440788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
    Kar S; Bhatt DL
    Coron Artery Dis; 2012 Sep; 23(6):380-90. PubMed ID: 22728913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel direct-acting anticoagulants for risk reduction in ACS.
    Dobesh PP; Oestreich JH
    J Pharm Pract; 2013 Aug; 26(4):358-66. PubMed ID: 23172897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet options for secondary prevention in acute coronary syndromes.
    Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.